JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics
Thomas McKerrell(Wellcome Sanger Institute), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Paul Costeas(Deakin University), Kiki Melanthiou(Nicosia General Hospital), Thaidy Moreno-Rodriguez(Instituto de Biomedicina y Biotecnología de Cantabria), Grace Collord(University College Hospital), Ignacio Varela(Wellcome Sanger Institute), Naomi Park(Wellcome Sanger Institute), João M.L. Dias(Centro Hospitalar do Porto), Marios Antoniades(Nicosia General Hospital), Hannes Ponstingl(Wellcome Sanger Institute), Petroula Gerasimou(Center for the Study of Childhood and Adolescence), Jianxiang Chi(Center for the Study of Childhood and Adolescence), Chrystalla Prokopiou(Limassol General Hospital)
Cited by 58
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
The Life History of 21 Breast Cancers
|Cell|2012|1.5k